Endobronchial valve use in COVID-19 related pneumothorax and persistent air leak.
Timothy S NugentM AladailehN E DonlonN MurphyD EatonPublished in: Annals of the Royal College of Surgeons of England (2021)
Pneumothoraces may occur rarely in coronavirus (COVID-19) patients, often resulting from a combination of fibrotic parenchymal changes and prolonged high-pressure ventilation. Very few studies have been published describing the management of pneumothorax in the novel COVID-19 pneumonia patients. Although chest drain insertion represents the first line of treatment, a persistent pneumothorax and air leak requiring intervention could be managed by a thoracoscopic procedure or, as is the case here, by endobronchial valve insertion. Endobronchial valve insertion is a minimally invasive technique that provides a treatment option in patients with severe parenchymal COVID-19 related lung disease. As far as the authors are aware this is the first report of the use of endobronchial valves in a COVID-19 patient.
Keyphrases
- sars cov
- coronavirus disease
- aortic valve
- ultrasound guided
- minimally invasive
- mitral valve
- respiratory syndrome coronavirus
- end stage renal disease
- randomized controlled trial
- newly diagnosed
- chronic kidney disease
- transcatheter aortic valve replacement
- fine needle aspiration
- case report
- respiratory failure
- intensive care unit
- combination therapy
- transcatheter aortic valve implantation
- systematic review